EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management

Isabel Estragués-Gázquez, José Contador, Leidy Dayana Martínez, Aida Fernández-Lebrero, Greta García-Escobar, Irene Navalpotro-Gómez, Oriol Grau-Rivera, Gianmarco Iaccarino, Rosa Maria Manero-Borràs, Paula Ortiz-Romero, Felipe Hernández-Villamizar, Javier Torres-Torronteras und 8 weitere

JAMA Neurology · 01.11.2026 · 83 (11) · 1099

DOI: 10.1001/jamaneurol.2026.3497 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Neurology, erschienen am 01.11.2026. Verfasst von Isabel Estragués-Gázquez und 19 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Brain Health Center, Department of Neurology, Hospital del Mar, Barcelona, Spain. Hauptthemen laut MEDLINE: tau Proteins, Cognitive Dysfunction, Alzheimer Disease, Neurofilament Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Blood-based biomarkers show high performance for detecting Alzheimer disease (AD) pathology, but evidence on their impact on diagnostic certainty, clinical management, and emotional outcomes in routine care is limited.

Objective

To determine whether earlier disclosure of plasma phosphorylated tau at threonine 217 (p-tau217) and neurofilament light chain (NfL) increases etiologic diagnostic certainty, influences clinical management, and affects emotional outcomes in individuals evaluated for cognitive symptoms. Design, Setting, and Participants This was a prospective randomized clinical trial conducted at a single memory clinic in Spain between February and October 2024, with 9 months of follow-up. Consecutive new outpatients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or mild dementia without a prior etiologic diagnosis were enrolled. Of 265 eligible participants, 220 were randomized to earlier disclosure of blood-based biomarkers at the 3-month visit or delayed disclosure at the 9-month visit.

Intervention

Disclosure of blood-based biomarkers for AD pathology (p-tau217) and neurodegeneration (NfL) to the treating neurologist and participant, alongside standard clinical evaluation. Main Outcomes and Measures The primary outcome was the proportion of participants achieving a very high-confidence etiologic diagnosis (≥90%). Secondary outcomes included changes in clinical management and emotional outcomes (anxiety, depression, perceived stress, and quality of life).

Results

Among the 220 randomized participants (median [IQR] age, 73 [68-78] years; 123 [55.9%] women), baseline diagnoses were SCD (100 [45.5%]), MCI (68 [30.9%]), and mild dementia (52 [23.6%]). At 3 months, a very high-confidence etiologic diagnosis was achieved in 56 of 112 participants in the earlier-disclosure arm (50.0%) compared with 5 of 108 in the delayed-disclosure arm (4.6%) ( P < .001). Diagnostic certainty converged after disclosure in both arms, except among participants with MCI, in whom higher certainty persisted in the earlier-disclosure arm. Earlier disclosure was associated with more frequent initiation of symptomatic AD treatment (16/112 [14.3%] vs 5/108 [4.6%]; difference, 9.7; 95% CI, 1.8 to 17.8; P = .01), fewer planned follow-up neuropsychological reassessments for diagnostic clarification (34/112 [30.4%] vs 57/108 [52.8%]; difference, −22.4; 95% CI, −34.4 to −9.4; P < .001), and more planned discharge from the memory clinic to primary care (35/112 [31.3%] vs 13/108 [12.0%]; difference, 19.2; 95% CI, 8.4 to 29.5; P < .001). Earlier disclosure was not associated with worse emotional outcomes. Conclusions and Relevance In this randomized clinical trial, earlier disclosure of blood-based biomarkers increased etiologic diagnostic certainty and led to earlier, targeted clinical management without increasing emotional distress. These findings support the integration of blood-based biomarkers into memory clinic diagnostic pathways. Trial Registration ClinicalTrials.gov Identifier: NCT06246019

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsCognitive DysfunctionAlzheimer DiseaseNeurofilament ProteinsHumansFemaleBiomarkersMaleAgedProspective StudiesReturn of Individual Research ResultsAged, 80 and over

Substanzen

Biomarkerstau ProteinsNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Barcelona Brain Health Center, Department of Neurology, Hospital del Mar, Barcelona, Spain.
  • Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
  • Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Laboratori de Referència de Catalunya, Barcelona, Spain.

Zitieren

APA

Estragués-Gázquez, I., Contador, J., Martínez, L. D., Fernández-Lebrero, A., García-Escobar, G., Navalpotro-Gómez, I., Grau-Rivera, O., Iaccarino, G., Manero-Borràs, R. M., Ortiz-Romero, P., Hernández-Villamizar, F., Torres-Torronteras, J., de Diego-Osaba, M., Blasco-Forniés, H., Jiménez-Moyano, E., Hernández, J. J., Padrós, A., Del Campo, M., Puig-Pijoan, A., & Suárez-Calvet, M. (2026). Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management. JAMA Neurology, 83(11), 1099. https://doi.org/10.1001/jamaneurol.2026.3497

Vancouver

Estragués-Gázquez I, Contador J, Martínez LD, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, et al. Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management. JAMA Neurology. 2026;83(11):1099. doi:10.1001/jamaneurol.2026.3497

BibTeX
@article{EstragusGzquez2026,
  author = {Estragués-Gázquez, Isabel and Contador, José and Martínez, Leidy Dayana and Fernández-Lebrero, Aida and García-Escobar, Greta and Navalpotro-Gómez, Irene and Grau-Rivera, Oriol and Iaccarino, Gianmarco and Manero-Borràs, Rosa Maria and Ortiz-Romero, Paula and Hernández-Villamizar, Felipe and Torres-Torronteras, Javier and de Diego-Osaba, Marina and Blasco-Forniés, Helena and Jiménez-Moyano, Esther and Hernández, Juan José and Padrós, Anna and Del Campo, Marta and Puig-Pijoan, Albert and Suárez-Calvet, Marc},
  title = {Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management},
  journal = {JAMA Neurology},
  year = {2026},
  volume = {83},
  number = {11},
  pages = {1099},
  doi = {10.1001/jamaneurol.2026.3497}
}
Kostenlos starten →